Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT06959199

Endovascular Treatment Beyond 24 Hours for Acute Ischemic Stroke Caused by Anterior Circulation Large Vessel Stenosis

Led by The Second Hospital of Anhui Medical University · Updated on 2025-05-14

432

Participants Needed

1

Research Sites

248 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Endovascular therapy (EVT) is currently recommended as the first-line treatment for patients with acute large vessel occlusion (LVO) in the anterior circulation within 24 hours of symptom onset. However, the therapeutic benefit of EVT beyond 24-hour window remains uncertain due to limited evidence. The EVT-BELATED trial is a multicenter, prospective, randomized, open-label, blinded end-point (PROBE) study designed to assess the safety and efficacy of EVT in patients with acute ischemic stroke (AIS) caused by anterior circulation LVO presenting beyond 24 hours after symptom onset.

CONDITIONS

Official Title

Endovascular Treatment Beyond 24 Hours for Acute Ischemic Stroke Caused by Anterior Circulation Large Vessel Stenosis

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age > 18 years
  • Acute ischemic stroke with symptom onset or last known well time between 24 to 120 hours, or progressive ischemic stroke 24 hours to 7 days with at least a 4-point increase in NIHSS
  • NIHSS score between 5 and 25
  • Occlusion or 70% stenosis of the internal carotid artery or middle cerebral artery (M1/M2) confirmed by imaging and responsible for the stroke
  • Meet specific imaging criteria based on MRI, CTA, or CTP showing limited infarct size and good collateral blood flow
  • Signed informed consent obtained
Not Eligible

You will not qualify if you...

  • Pre-stroke modified Rankin Scale score of 2 or higher
  • Unable to undergo vascular imaging
  • Allergies to iodine contrast, anesthetics, or contraindications to endovascular treatment
  • Prior endovascular therapy during current hospitalization
  • Intracranial hemorrhage on initial imaging
  • Platelet count below 50x10^9/L, bleeding disorders, or high INR (>3.0) due to anticoagulation
  • Refractory hypertension with very high blood pressure despite treatment
  • History of intracranial hemorrhage within past 3 months
  • Significant brain swelling causing midline shift confirmed by imaging
  • Suspected cardioembolic stroke or non-atherosclerotic causes like arterial dissection or vasculitis
  • Prior intracranial stent in the same vessel
  • Major surgery within past 30 days
  • Pregnant or currently breastfeeding
  • Severe other illnesses with life expectancy under 3 months
  • Deemed unsuitable for participation by the investigator for any reason

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

The Second (Affiliated) Hospital of Anhui Medical University

Hefei, Anhui, China, 230031

Actively Recruiting

Loading map...

Research Team

Q

Qi Li, professor

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here